ClinicalTrials.gg
Active, not recruitingNCT06448754eVOLVE-01Updated Sep 29, 2026

Volrustomig Priming Regimens Exploratory Phase II Platform Study

A Phase 2 interventional study of Volrustomig and Carboplatin in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 63 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
55th of 137
194 · median 152
Started
2024
with 19 others
Phase 2
38 of 209
2 open now
Primary completion
2027-07
later than 48 of 77 live
Registered
184th of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 55th largest by enrollment of the 137 interventional ones that give a count, is one of 20 that started in 2024, is one of 38 in phase 2, reaches primary completion later than 48 of the 77 other live ones, and was the 184th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Read the detailed description

This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.

This platform study currently includes 2 substudies:

Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.

Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.

All arms will test a volrustomig dosing in combination with chemotherapy.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Solid Tumor
  • Programmed cell death-ligand-1
  • Tumor proportion score
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0 or 1 with no deterioration.
  • greater than or equal to (>=) 12 weeks.
  • Adequate organ and bone marrow function.
  • Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
  • or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
  • Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
  • Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
  • At least one not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.

Key Exclusion Criteria:

  • Spinal cord compression.
  • History of primary active immunodeficiency.
  • Active or prior documented or inflammatory disorders.
  • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
  • unless asymptomatic, stable, and not requiring for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
  • Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, , or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed

    Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.

    Drug: Volrustomig · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed

    Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.

    Drug: Volrustomig · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel

    Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel).

    Drug: Volrustomig · Drug: Carboplatin · Drug: Pemetrexed · Drug: Ramucirumab · Drug: Paclitaxel

Interventions

  • Participants will receive volrustomig via intravenous (IV) infusion.

    Also known as: MEDI5752

  • Participants will receive carboplatin via IV infusion.

  • Participants will receive pemetrexed via IV infusion.

  • Participants will receive ramucirumab via IV infusion.

  • Participants will receive paclitaxel via IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed.

    Time frame: From screening (Days -28 to Day -1) up to 2 year 10 months

  2. Confirmed Objective Response rate (ORR)

    ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

    Time frame: Up to 2 year 10 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose.

    Time frame: Up to 2 year 10 months

  2. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression).

    Time frame: Up to 2 year 10 months

  3. Progression Free Survival (PFS)

    PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression).

    Time frame: Up to 2 year 10 months

  4. Overall Survival (OS)

    OS is defined as the time from randomization or first dose until the date of death due to any cause.

    Time frame: Up to 2 year 10 months

  5. Serum Concentration of Volrustomig

    The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

    Time frame: Up to 2 year 10 months

  6. Trough concentration (Ctrough)

    The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

    Time frame: Up to 2 year 10 months

  7. Maximum Observed Concentration (Cmax)

    The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

    Time frame: Up to 2 year 10 months

  8. Area Under the Curve (AUC)

    The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

    Time frame: Up to 2 year 10 months

  9. Number of Participants with Positive Antidrug Antibodies (ADAs)

    The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed.

    Time frame: Up to 2 year 10 months

07

Study locations

63 sites
  • Research Site
    Los Angeles, California 90067, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Beijing, 100730, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Jinan, 250013, China
  • Research Site
    Yantai, 264000, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Bois-Guillaume, 76031, France
  • Research Site
    Caen, 14076, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Batumi, 6010, Georgia
  • Research Site
    Tbilisi, '0159, Georgia
  • Research Site
    Tbilisi, 0112, Georgia
  • Research Site
    Tbilisi, 0114, Georgia
  • Research Site
    Tbilisi, 0144, Georgia
  • Research Site
    Tbilisi, 186, Georgia
  • Research Site
    Athens, 115 27, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Elaiones, 546 23, Greece
  • Research Site
    Piraeus, 185 47, Greece
  • Research Site
    Thessaloniki, 57001, Greece
  • Research Site
    Genoa, 16132, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Perugia, 06132, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Perai, 13700, Malaysia
  • Research Site
    Lisbon, 1169-050, Portugal
  • Research Site
    Lisbon, 1400-038, Portugal
  • Research Site
    Lisbon, 1649-035, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Cluj-Napoca, 400641, Romania
  • Research Site
    Craiova, 200542, Romania
  • Research Site
    Floreşti, 407280, Romania
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Seongnam, 13620, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Suwon, 16247, South Korea
  • Research Site
    A Coruña, 15009, Spain
  • Research Site
    Alcorcón, 28922, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Málaga, 29004, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Valencia, 46015, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Geneva, 1205, Switzerland
  • Research Site
    Lausanne, 1011, Switzerland
  • Research Site
    Winterthur, 8401, Switzerland
  • Research Site
    Zurich, 8091, Switzerland
  • Research Site
    Changhua, 50006, Taiwan
  • Research Site
    New Taipei City, 23561, Taiwan
  • Research Site
    Taipei, 106, Taiwan
  • Research Site
    Taipei, 110, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 7, 2024
StartActual
Aug 27, 2024
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06448754
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Aug 27, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion